CoChat

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

‡ · 2005 · The Lancet

The DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.

Abstract

Background Patients with type 2 diabetes mellitus are at increased risk of cardiovascular disease, partly owing to dyslipidaemia, which can be amenable to fibrate therapy. We designed the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study to assess the effect of fenofibrate on cardiovascular disease events in these patients. Methods We did a multinational, randomised controlled trial with 9795 participants aged 50-75 years, with type 2 diabetes mellitus, and not taking statin therapy at study entry. After a placebo and a fenofibrate run-in phase, we randomly assigned patients (2131 with previous cardiovascular disease and 7664 without) with a total-cholesterol concentration of 3.0-6.5 mmol/L and a total-cholesterol/HDL-cholesterol ratio of 4.0 or more or plasma triglyceride of 1.0-5.0 mmol/L to micronised fenofibrate 200 mg daily (n=4895) or matching placebo (n=4900). Our primary outcome was coronary events (coronary heart disease death or non-fatal myocardial infarction); the outcome for prespecified subgroup analyses was total cardiovascular events (the composite of cardiovascular death, myocardial infarction, stroke, and coronary and carotid revascularisation). Analysis was by intention to treat. The study was prospectively registered (number ISRCTN 64783481). Findings Vital status was confirmed on all but 22 patients. Averaged over the 5 years' study duration, similar proportions in each group discontinued study medication (10% placebo vs 11% fenofibrat…

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(05)67667-2

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

59 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 36 references

Cited by

See all 3,284

Metadata

Authors
‡
Corresponding author
‡
Venue
The Lancet
Publisher
Elsevier BV
Published
2005-11
Volume
366
Issue
9500
Pages
1849-1861
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2198678228
Cited by
3,284
References
37
Citations by year
2026: 78 · 2025: 97 · 2024: 89 · 2023: 126 · 2022: 99 · 2021: 107 · 2020: 130 · 2019: 117 · 2018: 129 · 2017: 133 · 2016: 140 · 2015: 149 · 2014: 182 · 2013: 182 · 2012: 207
FWCI
217.14
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • UWA Profiles and Research Repository (UWA) (submittedVersion)
  • ANU Open Research (Australian National University) (submittedVersion)
  • Griffith Research Online (submittedVersion)
Funders
Diabetesliitto
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
fenofibrate, type 2 diabetes, cardiovascular disease, myocardial infarction, coronary artery disease, dyslipidemia, fibrates, lipid-lowering therapy, statins, cardiovascular events, fieldwork, cardiovascular risk reduction, treatment discontinuation, secondary prevention, primary prevention, older adults, cardiovascular mortality, stroke, carotid revascularization
MeSH terms
Aged, Hypolipidemic Agents, Cardiovascular Diseases, Cholesterol, Coronary Disease, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Humans, Male, Middle Aged, Fenofibrate, Triglycerides, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Dyslipidemias

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. https://app.cochat.ai/papers/10.1016/s0140-6736(05)67667-2
The paper
‡. (2005). Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. The Lancet. https://doi.org/10.1016/s0140-6736(05)67667-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.